NICE TA578: Locally advanced, unresectable non-small cell lung cancer after platinum-based chemoradiation. (Decision date - June 2019).
NICE TA798: Durvalumab for maintenance treatment of unresectable
non-small-cell lung cancer after platinum-based chemoradiation. (NHSE
commissioned). (Decision date - July 2022).
DO NOT PRESCRIBE (DNP):
NICE TA662: in combination for untreated extensive-stage small cell lung cancer. (Terminated appraisal). (Decision date - December 2020).
Red Drug Classifications
8. NHS England commissioned – to be used in line with NHSE commissioning intentions